Amudha DEIVASIGAMANIMuthukumar RAJASEKARANMin FENG Shuiping LIU
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and presents a great public health and social burden. HCC is an epithelial cancer originating from hepatocytes and has been postulated to result from a series of genetic alterations attributable to a diverse range of causes. HCC is a highly therapyresistant cancer. Surgical treatments, including hepatic resection and orthotopic liver transplantation, provide the best option for cure in selected patients; yet, the long-term, disease-free survival rate remains unsatisfactory. Tumour recurrence and metastases are the major complications in more than two-thirds of these patients, with a poor prognosis and no proven effective survival-prolonging treatment modality available. There is indeed a great unmet need for new effective therapies for HCC. To tackle HCC, our laboratory employs unbiased, genome-wide strategies to identify key genes/regulatory pathways that are altered in relevant human HCC tissues. Further, we seek to understand how these changes affect the carcinogenesis of HCC, with the aim to modulate these regulatory pathways against the disease. We have systematically gathered molecular evidence and, through clinical corroboration of the data, have discovered molecular biomarkers that can provide clinically meaningful avenues for designing strategies independently from clinical risk factors. This, in turn, can be used to decipher the underlying molecular networks leading to HCC recurrence and identify reliable diagnostic and prognostic molecular biomarkers to develop novel therapeutics for HCC (Figure 1).
Shiying HuangJieLing PanHuixin LauJung Yi ONGJoshua WEE Aik Liang
The laboratory unit for the Paediatric Brain Tumour Research Office (PBTRO), SingHealth Duke-NUS Academic Medical Centre was established in 2015, with competitive grants secured. We are a dynamic laboratory unit and have steadily expanded our team and international collaborations over the past few years. Our goal in research is to derive findings that enable a reflective change in the practice of medicine in brain tumours. Our team (PBTRO) shares a common dream to present globally competitive research findings in the field of neurooncology, addressing these areas in the practice of medicine through science. We work on several types of brain tumours, both in paediatric and adult populations. One major research focus of our group is in the brain tumour microenvironment, translating research findings in tumour biology and genomics to bedside benefits for patients with brain tumours. Our research combines genomic methodologies and mouse models to study the complex regulation and developmental biology of brain tumours. We place a large emphasis on the preclinical development of therapeutics for brain tumours that currently have no cures, drawing from various strengths in genomics, high throughput functional assays optimised in our laboratory, and a large, unique cohort of patient-derived orthotopic mouse models of brain tumours developed for preclinical testing.
EXCERPT FROM PBTRO TEAM MEMBERS & INTERN STUDENTS
“Our work focuses on cell culture and utilises molecular techniques to unravel the cell biology behind the drug effects on brain tumours; this is in line with our team goal to discover effective and novel treatments for the benefit of patients.”
“The most important insight I learnt from this internship was realising the tenacity of character required to become a successful researcher. Their passion for their work, and their grit and perseverance constantly inspire me to work hard in my studies knowing that my study now is not as challenging as the lives of these researchers.”
Our Work at Laboratory 609-T, Laboratory Unit of Pediatric Brain Tumour Research Office, SingHealth Duke-NUS Academic Medical Centre
*Denotes publications where Teo WY is a corresponding author
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Crescent, Singapore 169610 +65 6436 8000